Form EFFECT Damora Therapeutics,
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 12, 2026 |
| Accession Number: | 0001193125-26-342562 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen for Acute Infectious Conjunctivitis
- Impactful Storytelling — Kiss the Ground's Brand Awareness Jumps from 8% to 13%, Propelling the Growth of the Regenerative Movement
- LUXEED Super Factory: Manufacturing Confidence for European Market Expansion
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share